Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23317410 | 1.00 | GPR119 (0.34) | GPR119HDAC8ACACBMEN1KMT2A | |
| SCHEMBL23317407 | 0.90 | ACACB (0.33) | GPR119HDAC8ACACBPIK3R1PIK3CA | |
| SCHEMBL23304726 | 0.87 | MAPT (0.32) | — | |
| SCHEMBL31059155 | 0.86 | ACACB (0.34) | GPR119HDAC8ACACBMEN1KMT2A | |
| SCHEMBL31059139 | 0.86 | ACACB (0.35) | GPR119HDAC8ACACBPIK3R1PIK3CA | |
| SCHEMBL23317472 | 0.86 | ACACB (0.35) | GPR119HDAC8ACACBPIK3R1PIK3CA | |
| SCHEMBL23317063 | 0.86 | ACACB (0.34) | GPR119HDAC8ACACBMEN1KMT2A | |
| SCHEMBL31059151 | 0.85 | ACACB (0.33) | GPR119HDAC8ACACBMEN1KMT2A | |
| SCHEMBL23317062 | 0.85 | ACACB (0.33) | GPR119HDAC8ACACBMEN1KMT2A | |
| SCHEMBL23317400 | 0.84 | GPR119 (0.34) | GPR119HDAC8ACACBPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929709-B | Spirocyclic O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranoside inhibitors | 比奥根MA公司 | 2024-08-30 | — | — | CN | disclosed |